Details for Patent: 9,708,342

« Back to Dashboard

Which drugs does patent 9,708,342 protect, and when does it expire?

Patent 9,708,342 protects BIKTARVY, BIXLENVO, and BIXLENVO SUNLENCA STARTER PACK (COPACKAGED), and is included in three NDAs.

This patent has sixty-two patent family members in forty-two countries.

Summary for Patent: 9,708,342

Title:	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Abstract:	The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3] oxazepin-8-olate Form I and the therapeutic uses thereof.
Inventor(s):	Ernest A. Carra, Irene Chen, Vahid Zia
Assignee:	Gilead Sciences Inc
Application Number:	US14/744,915
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,708,342
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,708,342

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No			Y	Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	BIXLENVO	bictegravir sodium; lenacapavir sodium	TABLET;ORAL	221104-001	Aug 27, 2026		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,708,342

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	100903
Australia	2015276860
Australia	2018203175